Michael Weintraub, MDs Post New Trial Results STEP-HFpEF DM published in NEJM today Semaglutide improved heart failure symptoms and physical limitations in patients with obesity, HFpEF and Type 2 Diabetes 6.4% weight over placebo CRP 6 min walk distance These results are consistent with findings of a prior trial of semaglutide in HFpEF and obesity without type 2 diabetes
Where do they differ in side effects
The Effects of Ultrasound on Metabolism, Anhthu Cung, Quonte Watkins, John Cressman 29
Its active ingredient is a proprietary yeast-derived compound the manufacturer calls "EV1 Peptide," which the company describes as designed to mimic the body's natural appetite-regulating hormones through the gut
Whats even more interesting is that GLP-1 medications have the potential to make a profound impact on broader lifestyle choices in other areasfor example, by influencing alcohol and tobacco consumption
Others continue losing beyond twelve months toward more aggressive targets